Aerska develops targeted RNA medicines to treat brain diseases. By silencing genes that cause harm, we can preserve the minds and memories of those we love.
Location: Ireland
Total raised: $21M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.10.2025 | Seed | $21M | Ada Ventur... |
Mentions in press and media 5
| Date | Title | Description |
| 06.10.2025 | Aerska Secures $21M to Transform Neurological Disease Treatment with RNAi | Dublin-based biotech Aerska raised $21 million in seed financing. This significant capital boost targets groundbreaking RNA interference (RNAi) medicines. The company aims to redefine neurological disease treatment. Aerska employs innovativ... |
| 06.10.2025 | Aerska Raises $21M in Seed Financing | Aerska, a Dublin, Ireland-based biotechnology company improving the treatment of neurological diseases, raised $21M in seed financing. The round was co-led by Age1, Backed VC and Speedinvest, with participation from Blueyard, Lingotto (Exor... |
| 01.10.2025 | Irish biotech Aerska raises $21m to tackle neurological diseases | Irish biotech start-up Aerska has raised $21m (€19.5m) in seed funding to advance new genetic medicines aimed at treating and preventing neurological diseases such as Alzheimer’s and Parkinson’s. The company, founded by Irish entrepreneur J... |
| 01.10.2025 | Irish BioTech Aerska launches with €17 million to develop RNAi medicines for diseases of the brain | Aerska, a Dublin-based BioTech company aiming to redefine the treatment of neurological diseases, today announced it has raised €17 million in Seed financing to develop systemically administered RNA interference (RNAi) medicines designed to... |
| - | Aerska | “Aerska develops targeted RNA medicines to treat brain diseases. By silencing genes that cause harm, we can preserve the minds and memories of those we love.” |